Price Vision Group Participating in Clinical Study of Investigational Growth Factor Treatment for Eye Disorder, Fuchs Endothelial Corneal Dystrophy

Price Vision Group,Research

Indianapolis, IN – March 10, 2021 – Price Vision Group announced today that it is the first site to initiate patient treatment in a clinical trial evaluating use an experimental drug treatment in conjunction with a surgical procedure that treats the back surface of the cornea to restore vision in patients with a condition called…

Read More

Trefoil Therapeutics Partners With Price Vision Group for Patients with Corneal Endothelial Dystrophies

Cornea Transplantation,Price Vision Group

Trefoil Therapeutics Begins First Clinical Trial at Price Vision Group for Patients with Corneal Endothelial Dystrophies SAN DIEGO–(BUSINESS WIRE)–Trefoil Therapeutics today announced it has initiated the first clinical trial of its engineered Fibroblast Growth Factor-1 TTHX1114 for the treatment of people with corneal endothelial dystrophies (CED), including Fuchs Endothelial Corneal Dystrophy. T

Read More

Dr. Francis W. Price, Jr. to Receive Thomas C. Hasbrook Award

Price Vision Group

INDIANAPOLIS—Bosma Enterprises, an Indianapolis-based nonprofit organization dedicated to creating opportunities for Hoosiers who are blind or visually impaired, is set to honor two prominent supporters at its annual Hasbrook Awards Luncheon. The event will be held Nov. 2 at The Crane Bay, 551 W. Merrill St., Indianapolis, to raise funds for employment and training programs.

Read More